Aligos Therapeutics, Inc. is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.
Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners. The company’s lead program for chronic hepatitis B (CHB) employs a combination approach to silence viral genes and stimulate immune clearance. In parallel, Aligos is progressing antiviral candidates for respiratory viruses, including coronaviruses and influenza, by targeting key viral enzymes and immune pathways.
Aligos’s clinical development strategy emphasizes combination regimens that may offer functional cures rather than life‐long treatment. Its respiratory virus portfolio includes direct‐acting antivirals targeting viral polymerases, alongside immune modulators intended to enhance host defense mechanisms. By integrating novel chemistries with established antiviral targets, the company aims to deliver differentiated therapies across multiple indications.
With clinical trials conducted in North America and partnerships extending to global research centers, Aligos is focused on generating robust data to support regulatory filings. The management team brings deep experience in antiviral drug development, clinical operations and regulatory strategy, positioning the company to advance its mission of developing innovative solutions for patients living with chronic and acute viral diseases.
AI Generated. May Contain Errors.
Free ALGS Stock Alerts